Richard Houghton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5576520/publications.pdf

Version: 2024-02-01

949033 1181555 10 457 11 14 citations h-index g-index papers 14 14 14 388 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Fumarate Metabolic Signature for the Detection of Reed Syndrome in Humans. Clinical Cancer Research, 2020, 26, 391-396.	3.2	11
2	Determination of avibactam and ceftazidime in human plasma samples by LC–MS. Bioanalysis, 2015, 7, 1423-1434.	0.6	39
3	7th GCC Insights: incurred samples use; fit-for-purpose validation, solution stability, electronic laboratory notebook and hyperlipidemic matrix testing. Bioanalysis, 2014, 6, 2713-2720.	0.6	16
4	Recommendations on incurred sample stability (ISS) by GCC. Bioanalysis, 2014, 6, 2385-2390.	0.6	26
5	Efficacy of plasma phospholipid removal during sample preparation and subsequent retention under typical UHPLC conditions. Bioanalysis, 2012, 4, 795-807.	0.6	29
6	Recommendations on bioanalytical method stability implications of co-administered and co-formulated drugs by Global CRO Council for Bioanalysis (GCC). Bioanalysis, 2012, 4, 2117-2126.	0.6	29
7	Recommendations on ISR in multi analyte assays, QA/bioanalytical consultants and GCP by Global CRO Council for Bioanalysis (GCC). Bioanalysis, 2012, 4, 1723-1730.	0.6	21
8	Recommendations on the interpretation of the new European Medicines Agency Guideline on Bioanalytical Method Validation by Global CRO Council for Bioanalysis (GCC). Bioanalysis, 2012, 4, 651-660.	0.6	37
9	Recommendations on: internal standard criteria, stability, incurred sample reanalysis and recent 483s by the Global CRO Council for Bioanalysis. Bioanalysis, 2011, 3, 1323-1332.	0.6	78
10	Generic approach to validation of small-molecule LC–MS/MS biomarker assays. Bioanalysis, 2009, 1, 1365-1374.	0.6	65